Neurolens Headache Study

Status Completed

Clinical Trial Summary

To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Chronic Headaches. It is a Prospective randomized double masked two arm performed on a minimum of 200 to a maximum of 300 subjects identified as symptomatic (HIT-6 questionnaire score equal to or greater than 56) done across 3-15 clinical sites. There are two subgroups: a minimum of 100 in each subgroup (subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects (41-60 years).

Clinical Trial Description

This study is a two-arm crossover study with two subgroups. Subjects will initially be assessed for their headache symptoms (Headache Impact Test (HIT-6) questionnaire) and then are provided an updated refractive prescription and will wear them for 35 ± 5 days. Symptoms will be reassessed after the 35-day control break in. If the subject's symptoms have subsided, they will be exited from the study and will keep their lenses. Provided the subject has symptoms (HIT questionnaire score ≥ 56) after their 35-day use of their updated prescription and they continue to meet the inclusion/exclusion criteria they will proceed to the evaluation portion of the protocol. The first arm receiving neurolens first and the second arm receiving the control first. The control is a single vision or PAL lens which yields the BCDVA and BCNVA of a test subject with no prismatic correction. The neurolens prescribed prism will be based on the practitioner's Rx using the subject's best response to a prism trial lens and must be within a half prism diopter of the neurolens value output of the neurolens Measurement Device and providing the subject's BCDVA and BCNVA. Participants will come back after 35 day wear of their first test lens and the symptom questionnaire is reassessed. They will be now be crossed over to the second pair of study lenses (i.e. subjects in the first arm will not receive control lens and the ones in the second arm will not receive neurolens). Participants will come back after 35 day wear of their second test lens and the symptom questionnaire is reassessed for the final time. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05070767
Study type	Interventional
Source	Neurolens Inc.
Contact
Status	Completed
Phase	N/A
Start date	October 18, 2021
Completion date	May 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03472872` - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache	Phase 4
Withdrawn	`NCT05410366` - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn	`NCT02866084` - Neuromodulation Treatment of Vestibular Migraines	N/A
Active, not recruiting	`NCT03537573` - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care	N/A
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting	`NCT04352218` - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache	Phase 2
Completed	`NCT02734992` - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers	N/A
Completed	`NCT01153789` - Study of Oculomotor Dysfunction Leading to Children Vertigo	N/A
Completed	`NCT01327118` - Prostaglandin F2alpha in a Human Headache Model	N/A
Not yet recruiting	`NCT00969995` - Identification of Inflammatory Markers in Migraine Patients	N/A
Not yet recruiting	`NCT00752921` - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache	Phase 4
Completed	`NCT00212810` - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.	Phase 4
Terminated	`NCT00291395` - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers	Phase 1
Completed	`NCT00263094` - An End to the Yom Kippur (and Ramadan) Headache	N/A
Completed	`NCT00135122` - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache	Phase 3
Completed	`NCT02475005` - An Intervention to Improve Adolescent Headache Self-management	N/A
Completed	`NCT03163901` - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury	N/A
Completed	`NCT01664585` - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life	N/A
Completed	`NCT04632420` - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting	`NCT05033613` - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.